Analysts' Actions: AMGN BIIB DWA FCX ULTI

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Amgen ( AMGN) was upgraded at Goldman Sachs to buy from neutral. $130 price target. Company was also added to the Conviction Buy List, as the company has multiple potential catalysts, Goldman said.

Biogen Idec ( BIIB) was downgraded at Goldman Sachs to neutral from buy. $215 price target. Valuation call, as the stock is up 44% since December, Goldman said.

CapitalSource ( CSE) was downgraded to hold at TheStreet Ratings.

Dreamworks ( DWA) was upgraded at Bank of America/Merrill Lynch to neutral. $22 price target. Company appears to be at a positive inflection point, BofA/Merrill said.

Freeport-McMoran ( FCX) was upgraded at Nomura to buy from neutral. $38 price target. Company prices appear oversold, and valuation multiples should expand, Nomura said.

Fiserv ( FISV) was downgraded at Oppenheimer to perform from outperform. Valuation call, based on an $89 price target, Oppenheimer said.

LSI ( LSI) was downgraded at Goldman Sachs to neutral from buy. $7 price target. Company is leveraged to weak enterprise spending and lower PC demand, Goldman Sachs said.

Nuance ( NUAN) was downgraded at Morgan Stanley to equal-weight. Company is facing increased growth risks, Morgan Stanley said.

Oil States ( OIS) was downgraded at BMO Capital to underperform. Valuation call, based on an $82 price target, BMO Capital said.

Oneok ( OKE) was downgraded at Morgan Stanley to equal-weight. $53 price target. Stock is up 20% year to date, despite deteriorating fundamentals, Morgan Stanley said.

Opko Health ( OPK) was downgraded to hold at TheStreet Ratings.

Ultimate Software ( ULTI) was upgraded at Canaccord Genuity to buy. $110 price target. Company is carrying a lot of momentum into the new year, Canaccord said.

STOCK COMMENTS/EPS CHANGES

Aetna ( AET) estimates, price target were raised at BMO Capital. Shares are now seen reaching $64. Estimates were also increased, given improving core trends, BMO Capital said. Outperform rating.

Artisan Partners Asset Management ( APAM) price target and estimates were increased at Citigroup. Solid flows, underlying margin dynamics and favorable FCF, said Citigroup. Price target goes to $47.

Avon ( AVP) estimates, price target were boosted at BMO Capital. Shares are now seen reaching $27. Estimates were also increased, as the company is realizing higher margins, BMO Capital said. Outperform rating.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback